Vertex Protects Cystic Fibrosis Franchise by Acquiring CTP-656 from Concert
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 3 (Table of Contents)
Published: 23 Mar-2017
DOI: 10.3833/pdr.v2017.i3.2232 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Continuing its focus on cystic fibrosis treatments, Vertex Pharmaceuticals has acquired CTP-656, a Phase II cystic fibrosis transmembrane conductance regulator potentiator from Concert Pharmaceuticals...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018